A Study of Galcanezumab (LY2951742) in Participants With Migraine Headache

Inclusion Criteria:

- Participants with a history of migraine of at least 1 year prior to enrollment.

- Migraine onset prior to age 50.

Exclusion Criteria:

- Current enrollment in, or discontinuation within the last 30 days from, a clinical
trial involving any investigational drug or device.

- Current use or any prior exposure to any CGRP antibody, any antibody to the CGRP
receptor, or antibody to nerve growth factor (NGF).

- History of migraine subtypes including hemiplegic migraine, ophthalmoplegic migraine,
and basilar-type migraine.

- Have a history or presence of other medical illness that indicates a medical problem
that would preclude study participation.

- Failure to respond to more than two adequately dosed effective migraine prevention
treatments.

- Evidence of significant active psychiatric disease, in the opinion of the
investigator.

- Women who are pregnant or nursing.